

Identification and validation of candidate risk genes in endocytic vesicular trafficking associated with esophageal atresia and tracheoesophageal fistulas

Guojie Zhong,^{1,2,15} Priyanka Ahimaz,^{3,15} Nicole A. Edwards,^{4,15} Jacob J. Hagen,^{1,3} Christophe Faure,⁵ Qiao Lu,^{1,3} Paul Kingma,⁶ William Middlesworth,⁷ Julie Khlevner,⁸ Mahmoud El Fiky,⁹ David Schindel,¹⁰ Elizabeth Fialkowski,¹¹ Adhish Kashyap,⁴ Sophia Forlenza,^{6,12} Alan P. Kenny,^{6,12} Aaron M. Zorn,^{4,*} Yufeng Shen,^{1,13,*} and Wendy K. Chung^{3,14,*}

Summary

Esophageal atresias/tracheoesophageal fistulas (EA/TEF) are rare congenital anomalies caused by aberrant development of the foregut. Previous studies indicate that rare or *de novo* genetic variants significantly contribute to EA/TEF risk, and most individuals with EA/TEF do not have pathogenic genetic variants in established risk genes. To identify the genetic contributions to EA/TEF, we performed whole genome sequencing of 185 trios (probands and parents) with EA/TEF, including 59 isolated and 126 complex cases with additional congenital anomalies and/or neurodevelopmental disorders. There was a significant burden of protein-altering *de novo* coding variants in complex cases ($p = 3.3 \times 10^{-4}$), especially in genes that are intolerant of loss-of-function variants in the population. We performed simulation analysis of pathway enrichment based on background mutation rate and identified a number of pathways related to endocytosis and intracellular trafficking that as a group have a significant burden of protein-altering *de novo* variants. We assessed 18 variants for disease causality using CRISPR-Cas9 mutagenesis in *Xenopus* and confirmed 13 with tracheoesophageal phenotypes. Our results implicate disruption of endosome-mediated epithelial remodeling as a potential mechanism of foregut developmental defects. Our results suggest significant genetic heterogeneity of EA/TEF and may have implications for the mechanisms of other rare congenital anomalies.

Introduction

Esophageal atresia (EA) is a congenital abnormality of the esophagus, co-occurring with tracheoesophageal fistula (TEF) in 70%–90% cases.^{1,2} The overall worldwide incidence of EA/TEF is 2.4 per 100,000 births.³ Approximately 55% of individuals with EA/TEF are complex with additional congenital anomalies³ in the cardiovascular, musculoskeletal, urinary, gastrointestinal, or central nervous system.⁴ The genetic causes of EA/TEF include chromosome anomalies or variants in genes involved in critical developmental processes that are dosage sensitive.⁵ Several EA/TEF risk genes include the transcriptional regulators SOX2, MYCN, CHD7, FANCB, and members of FOX transcription factor family.^{2,5} VACTERAL frequently includes EA/TEF and is frequently of unknown etiology.

Mouse models have demonstrated that precise regulation of the transcription factors *Nkx2-1*, *Sox2*, and *Foxf1* by WNT, bone morphogenetic protein 4 (*BMP4*), and

Hedgehog signaling pathways is required for patterning of the fetal foregut and separation of the esophagus and trachea.^{3,6–9} Moreover, *EFTUD2* haploinsufficiency leads to syndromic EA. *EFTUD2* encodes one of the major components of the spliceosome, emphasizing the necessity of mRNA maturation through the spliceosome complex for normal development.¹⁰ Recently we have shown that *de novo* variants are major contributors to EA/TEF genetic risk, especially in genes that are targets of *SOX2* or *EFTUD2*.¹¹ However, it remains unclear how developmental signaling pathways, transcription factors, and RNA metabolism control the cellular behavior of tracheoesophageal morphogenesis.

Despite previous studies of the genetics in several syndromes that include EA/TEF and mouse models, the etiology in most cases of EA/TEF is still unexplained. To identify the genetic etiologies of EA/TEF, we performed whole genome sequencing (WGS) of 185 individuals with EA/TEF, most without a family history of EA/TEF, and their

¹Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA; ²Integrated Program in Cellular, Molecular, and Biomedical Studies, Columbia University, New York, NY, USA; ³Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA; ⁴Center for Stem Cell & Organoid Medicine (CuSTOM), Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; ⁵Division of Pediatric Gastroenterology, CHU Sainte-Justine, Montreal, QC, Canada; ⁶Division of Neonatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; ⁷Division of Pediatric Surgery, Columbia University Irving Medical Center, New York, NY, USA; ⁸Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, New York, NY, USA; ⁹Pediatric Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt; ¹⁰Division of Pediatric Surgery, UT Southwestern School of Medicine Dallas, Texas, USA; ¹¹Division of Pediatric Surgery, Oregon Health and Science University, Portland, OR, USA; ¹²Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA; ¹³Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA; ¹⁴Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA

¹⁵These authors contributed equally

*Correspondence: aaron.zorn@cchmc.org (A.M.Z.), ys2411@cumc.columbia.edu (Y.S.), wkc15@columbia.edu (W.K.C.)
<https://doi.org/10.1016/j.xhgg.2022.100107>.

© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



biological parents. We confirmed our previous results from a smaller EA/TEF cohort, demonstrating an overall enrichment of *de novo* coding variants in complex cases. Functional enrichment analysis identified a striking convergence of putative risk genes in biological pathways related to endocytosis, membrane dynamics, and intracellular transport. We then used CRISPR-generated *Xenopus* mutant models to successfully confirm 13 of 18 candidate risk genes for EA/TEF. Together with recent reports that endosome-mediated membrane remodeling is required for tracheoesophageal morphogenesis in animal models,¹² this suggest that disruptions in endosome trafficking may be a feature of many complex EA/TEF cases.

Methods

Participants recruitment

Individuals with EA/TEF were recruited as part of the CLEAR consortium from Columbia University Irving Medical Center in New York, USA, Center Hospitalier Universitaire Sainte-Justine in Montreal, Canada, Cincinnati Children's Hospital, in Ohio, USA, Cairo University General Hospital in Cairo, Egypt, University of Texas Southwestern Medical Center in Texas, USA, and Oregon Health and Science University in Portland, USA. Participants eligible for the study included those diagnosed with EA/TEF without an identified genetic etiology based upon medical record review. All participants provided informed consent. The overall study was approved by the Columbia University institutional review board and each affiliated site. Blood and/or saliva samples were obtained from the probands and both biological parents. A three-generation family history was taken at the time of enrollment, and clinical data were extracted from the medical records and by participant and parental interview.

We performed whole genome sequencing (WGS) on 185 probands without prior sequence based genetic testing diagnosed with EA/TEF and their parents. DNA from 75 probands was isolated from saliva samples, and DNA from the remaining 110 probands was isolated from blood samples. Individuals with only EA/TEF were classified as isolated cases (59 in total), and individuals with other type of congenital abnormalities or neurodevelopmental disorders were classified as complex cases (126 in total; Table S1).

WGS analysis

We identified *de novo* coding variants using previously published procedures with heuristic filters^{11,13,14} augmented with *in silico* confirmation by DeepVariant¹⁵ (Table S2). We used ANNOVAR and VEP to annotate variants with population allele frequency^{16,17} (gnomAD and ExAC), protein-coding consequences, and predicted damaging scores for missense variants. Variants were classified as LGD (likely gene disrupting, including frameshift, stop gained/lost, start lost, splice acceptor/donor and splicing damage variants [spliceAI¹⁸ DS score ≥ 0.8]), missense, or synonymous. In frame deletions/insertions (multiple of three nucleotides) and other splice region variants were excluded in the following analysis. Variants in olfactory receptor genes, HLA genes, or MUC gene family were filtered out of further analysis.

We identified *de novo* copy number variants (CNVs) customized pipeline as described in our previous study.¹⁹ Briefly, we applied CNVnator²⁰ (v0.3.3) with the bin size set as 100 bp to predict

CNV segments by read depth evidence and Lumpy²¹ v0.2.13 and SVtyper²² v0.1.4 to quantify pair-end/split-read (PE/SR) evidence. We only included the CNVs supported by both read depth and PE/SR in downstream analysis. Among the CNVs called in probands with Mendelian errors (that they were not called in any of the parents), we called *de novo* CNVs by visualization of both normalized read depth and allele fraction of SNP sites. We mapped *de novo* CNVs on GENCODE v29 protein-coding genes with at least 1 bp in the shared interval. We annotated the genes with variant intolerance metric by ExAC pLI,¹⁷ haploinsufficiency metric by Episcore,²³ haploinsufficiency and triplosensitivity of genes from ClinGen genome dosage map,²⁴ and CNV syndromes from DECIPHER²⁵ v11.1.

Burden test

We divided the cohort into two categories based on their phenotypes (isolated and complex) and performed burden tests on both groups and the aggregated group. For each group, we divided *de novo* coding variants into four types: synonymous, LGD, missense, and protein altering (defined as combination of LGD and missense variants). For each variant type, we calculated the expected number of variants based on a background mutation rate model.^{26,27} We used a single-sided Poisson test to test whether the number of observed *de novo* variants is significantly higher than expected. We performed the test in all genes, genes intolerant of loss-of-function variants ("constrained genes" based on gnomAD¹⁶ pLI ≥ 0.5), and non-constrained genes. Population attributable risk (PAR) was calculated as follows: $PAR = \frac{N_1 - N_2}{N}$, where N_1 , N_2 , N are the observed number of individuals with heterozygous protein-altering variants, expected number of individuals with heterozygous protein-altering variants, and the number of all cases, respectively.

Pathway enrichment analysis of *de novo* protein-altering variants in complex cases

To identify the pathways associated with *de novo* protein-altering variants, we performed pathway enrichment analysis on the gene ontology (GO) pathways and human phenotype ontology (HPO) terms from GSEA^{28,29} database (version v7.2) in complex cases. We only considered the pathways with at least two protein-altering variants (defined by combination of LGD and missense variants) expected by chance based on background mutation rate model.^{26,27} Based on these criteria, we selected a total of 907 pathways for downstream analysis. We performed a one-sided Poisson test of observed variants versus expectation in each pathway. Since many pathways have shared genes, we performed simulations under the null hypothesis to estimate the family-wise error rate (FWER) for a given p value. In each round, we randomly generated *de novo* LGD or missense variants based on the background mutation rate and calculated p values for each gene. Based on simulation results, we estimated FWER as follows:

$$FWER(p_0) = \frac{S(p \leq p_0)}{N}$$

where $S(p \leq p_0)$ is the total number of pathways that have p values smaller or equal to p_0 in all simulations, and N is the number of simulations. We used both Jaccard index and correlation to show the overlap of two pathways. For each pair of pathways, the Jaccard index was defined as the aggregated mutation rate of overlapping genes divided by aggregated mutation rate of all genes, and correlations were calculated as the Pearson correlation during

Table 1. Clinical table of 185 individuals enrolled into the study

Characteristics	N = 185
Mean age at enrollment (range)	8.22 years (2 days–54.5 years)
Sex	
Male	102 (55%)
Female	83 (45%)
Race and ethnicity	
White	149 (80.5%)
Black/African American	15 (8%)
Asian	11 (6%)
American Indian/Alaska Native	0
Native Hawaiian or Pacific Islander	0
More than one race	6 (3.2%)
Unknown	4 (2.2%)
Hispanic	13 (7%)
Non-Hispanic	169 (91.3%)
Unknown	3 (1.6%)
Type of EA/TEF	
Type A	27 (14.5%)
Type B	5 (2.7%)
Type C	97 (52.4%)
Type D	3 (1.6%)
Type H	8 (4.3%)
Unknown	45 (24.3%)
Clinical presentation	
Isolated	59 (32%)
Non-isolated	126 (68%)
Cardiac defects	65 (51.5%)
Skeletal defects	48 (38%)
Renal defects	40 (31.7%)
Neurodevelopmental delay	21 (16.6%)
Genitourinary defects	16 (12.7%)
Laryngotracheal defects	13 (10.3%)
Gastrointestinal defects	9 (7%)
Limb defects	7 (5.5%)
Neural tube defects	5 (3.9%)
Craniofacial defects	5 (3.9%)
Other	12 (9.5%)

simulation. Network layout is generated by “Prefuse Forced Directed OpenCL Layout” algorithm in Cytoscape.

Protein-protein interaction analysis

We tested protein interactions of *de novo* protein-altering variants in complex cases using S TRING(v11.0)³⁰ with default settings and

default interaction sources. Edges were filtered by S TRING score ≥ 0.4 and visualized by Cytoscape.³¹ Proteins that were not connected to any other genes after interaction filtration were removed from the network. Network layout was generated by “Prefuse Forced Directed OpenCL Layout” algorithm in Cytoscape. For each gene, Degree was calculated as the sum of all StringDB scores.

F0 *Xenopus tropicalis* CRISPR-Cas9 mutagenesis screen

All *Xenopus* experiments were performed using guidelines approved by the CCHMC Institutional Animal Care and Use Committee (IACUC 2019-0053). *Xenopus tropicalis* adult frogs were purchased from NASCO (USA) or raised in house and maintained in the CCHMC vivarium under normal housing conditions. *Xenopus* embryos were obtained by *in vitro* fertilization or natural mating as previously described.^{32,33} Germ line *sox2*^{2/−} embryos (F2 generation) were obtained by mating *sox2*^{+/-} adults obtained from the National *Xenopus* Resource (NXR, USA; RRID: SCR_013731).

For F0 CRISPR-Cas9 indel mutagenesis, guide RNAs (gRNAs) were designed using CRISPRScan³⁴ based on the *Xenopus tropicalis* v9.1 genome assembly on Xenbase.³⁵ gRNAs were designed to generate either null mutations (early in the coding sequence) or in the coding region similar to the corresponding mutation in our human cohort. *In vitro* transcribed gRNAs were synthesized using MEGAshortscript T7 Transcription Kit (ThermoFisher, USA) according to manufacturer’s instructions, or purchased as AltR-crRNA (Integrated DNA Technologies, USA). CrRNAs were annealed with AltR-tracrRNA prior to embryo injections according to manufacturer’s guidelines. Guide RNAs (500–700 pg) were complexed with recombinant Cas9 protein (1 ng, PNA Biosciences) and injected into *X. tropicalis* embryos at the one- or two-cell stage. For negative controls, a gRNA designed targeting tyrosinase (*tyr*) was injected to calculate a baseline percentage of defective tracheoesophageal development in *Xenopus* (~2%).

Three-day-old injected tadpoles (stage NF44) were fixed and processed for wholemount immunostaining as previously described¹² using the following primary antibodies: mouse anti-SOX2 (Abcam, ab79351, 1:1,000), goat anti-FOXF1 (R&D systems, AF4798, 1:300), and rabbit anti-NKX2-1 (SCBT, sc-13040X, 1:300). Imaging was performed using a Nikon A1 inverted LUNA confocal microscope with constant laser settings for all embryos. Image analysis was performed using NIS Elements (Nikon, USA). After image analysis, each embryo was genotyped by PCR amplification of the target region followed by Sanger sequencing. Since F0 CRISPR-mutagenesis is mosaic, different cells can have different mutations, so we used the Synthego ICE software tool³⁶ to deconvolute the proportion and sequence of each indel mutation in each embryo (Figure S1). Genotyping primers and gRNA sequences are in Table S3.

We only scored phenotypic data from embryos that had >40% mutation rate. For each gene, CRISPR-mutagenesis experiments were independently repeated at least twice in different batches of embryos, analyzing 5–15 individual mutant tadpoles per experiment. A candidate risk gene was determined to be likely causative if more than 10% of mutant tadpoles had a tracheal or esophageal defect (LTEC, occluded esophagus, failed separation), compared to the baseline rate of <2% in control injected tadpoles.

Results

A total of 185 individuals with EA/TEF were enrolled into the study, including 102 (55%) male and 83 (45%) female

Table 2. Burden of *de novo* variants in all cases

Variant type	All cases (n = 185)				Isolated cases (n = 59)				Complex cases (n = 126)			
	Obs	Exp	Fold	p value	Obs	Exp	Fold	p value	Obs	Exp	Fold	p value
Synonymous	58	61.6	0.94	0.7								
LGD	23	19.2	1.20	0.2	3	6.1	0.49	0.9	20	13.1	1.53	0.045
Missense	168	137.3	1.22	0.0062	44	43.8	1.0	0.51	124	93.5	1.33	0.0015
Protein altering (LGD + missense)	191	156.5	1.22	0.0042	47	49.9	0.94	0.68	144	106.6	1.35	3.3×10^{-4}

Burdens were calculated in all cases, isolated cases, and complex cases. Protein-altering variants were defined as LGD and missense variants. LGD is likely gene disrupting. Obs is observed. Exp is expected.

probands. Probands were between the ages of 2 days and 54.5 years with an average of 8.2 years old at enrollment (**Table 1**). The majority (52.4%) were type C EA/TEFs. Fifty-nine probands had isolated EA/TEF, and 126 probands had neurodevelopmental delay and/or at least one additional congenital anomaly and were classified as non-isolated. Of the non-isolated cases, the most common associated anomalies were congenital heart defects (65; 51.5%), skeletal defects (48; 38%), and renal defects (40; 31.7%). Other congenital anomalies included genitourinary defects (non-renal) (16; 12.7%), laryngotracheal defects (13; 10.3%), gastrointestinal defects (9; 7%), limb defects (7; 5.5%), neural tube defects (5; 3.9%), craniofacial defects (5; 3.9%), and other anomalies were seen in 12 probands (9.5%). Twenty-five probands (19.8%) had neurodevelopmental delay. Fifty-five of the cases (30%) previously had a normal clinical karyotype and/or chromosome microarray, and none had exome sequencing. The majority of probands were self-identified White (80.5%), and the remaining were Black/African American (8%), Asian (6%), more than one race (3.2%), or unknown (2.2%). One of the probands reported a family history of EA/TEF, and 14 reported a family history of other congenital anomalies.

Complex EA/TEF cases with additional anomalies have significant burden of *de novo* coding variants

We identified 249 *de novo* coding variants in 185 probands with EA/TEF (**Table S4**). The average number of *de novo* coding variants per proband is 1.35. We classified LGD and missense variants as protein-altering variants. We identified 191 protein-altering variants across all probands, including 47 in 59 isolated cases and 144 in 126 complex

cases. We identified 13 *de novo* CNVs variants in 134 probands, including two individuals with heterozygous deletions of 21q11. None of the CNVs overlapped with any of the genes with *de novo* sequence variants (**Table S5**).

We performed a burden test for enrichment of *de novo* coding variants in all cases, isolated cases, and complex cases respectively (**Table 2**). The number of synonymous variants is close to expectation (fold = 0.94, p = 0.7). Overall, there is a significant burden of *de novo* protein-altering variants (LGD or missense) (fold = 1.22, p = 4.2×10^{-3}). The burden is almost entirely observed in complex cases (fold = 1.35, p = 3.3×10^{-4}), as there is no evidence of *de novo* burden in isolated cases (fold = 0.94, p = 0.68). In complex cases (**Table 3**), the burden of LGD variants is mostly in genes that are intolerant of loss-of-function variants (defined as gnomAD¹⁶ pLI ≥ 0.5 , “constrained genes”; fold = 2.8, p = 2.3×10^{-3}), similar to other developmental disorders.³⁷ The burden of *de novo* missense variants is also higher in constrained genes compared to non-constrained genes (fold = 1.57 versus 1.22), although it is marginally significant in both constrained and non-constrained gene sets (p = 3.3×10^{-3} and 0.045, respectively). We estimate that about 38 genes carrying these variants in the complex cases are risk genes. Overall, *de novo* protein-altering variants explain about 30% of PAR of complex EA/TEF.

We assessed *de novo* protein-coding variants for pathogenicity using the ACMG criteria³⁸ (**Table 4** and **Table S6**). Of the 185 cases, only two clearly had a molecular diagnosis consistent with the phenotype (*EFTU2* and *MYCN* associated with mandibulofacial dysostosis, Guion-Almeida type [OMIM: 610536] and Feingold syndrome [OMIM: 164280],

Table 3. Burden of protein-altering *de novo* variants in complex cases stratified by gene variant intolerance

Gene group	Type of variants	Obs	Exp	Fold	p value
Constrained genes (pLI ≥ 0.5 ; n = 4,365)	LGD	11	3.9	2.82	0.0023
	missense	44	28.1	1.57	0.0033
	protein altering (LGD + missense)	55	32.0	1.72	1.4×10^{-4}
Non-constrained genes (n = 15,021)	LGD	9	9.2	0.98	0.57
	missense	80	65.5	1.22	0.045
	protein altering (LGD + missense)	89	74.6	1.19	0.057

Table 4. *De novo* LGD variants. LGD are likely gene disrupting

Gene	Variant	Protein	Variant type	CADD score	gnomAD pLI	OMIM	Individual phenotype	ACMG variant class
CAMK2B	c.558del	p.R187Afs*16	LGD	.	0.74	autosomal dominant mental retardation (607707)	EA + TEF type C, long gap, extra ribs, congenital scoliosis, developmental delay	pathogenic
GTF2I	c.761_762del	p.Q254Rfs*5	LGD	.	1	none	EA + TEF, atrial septal defect, bilateral inguinal hernia	VUS
AMER3	c.2236C > T	p.R746*	LGD	35	0.62	non-OMIM gene	EA + TEF, clubfeet, pectenotaxis, atrial septal defect, developmental delay	VUS
EFTUD2	c.2419del	p.Q807Rfs*21	LGD	.	1	mandibulofacial dysostosis, Guion-Almeida type (610536)	EA + TEF, clubfeet, pectenotaxis, atrial septal defect, developmental delay	pathogenic
ARHGAP21	c.1711C > T	,p.R571*	LGD	31	1	none	EA + TEF type C, multicystic dysplastic left kidney, patent ductus arteriosus	VUS
ARHGAP17	c.499C > T	pra9021	LGD	37	0.02	none	EA + TEF type C	VUS
MYCN	c.153_154insC	p.K52Qfs*3	LGD	.	0.89	Feingold syndrome (164280)	EA + TEF type C, microcephaly, clinodactyly, developmental delay	pathogenic
USP9X	c.4775del	p.G1592Vfs*4	LGD	.	1	X-linked mental retardation (300968)	EA, extra thumbs and dysmorphic features, rectus abdominis diastasis, severe laryngomalacia, seizures, hypotonia, intellectual disability	pathogenic
ADRM1	c.214-28_223del	.	LGD	.	1	none	EA + TEF type C, atrial septum defect, Ventricular septum defect, developmental delay	VUS
ADD1	c.1A > G	p.M1?	LGD	25.1	0.99	none	EA + TEF type C, vertebral anomalies, extra ribs, patent ductus arteriosus, horseshoe kidney, bilateral radial hypoplasia, thumb anomaly, imperforate anus	pathogenic
FBXO10	c.1419+1G > A	,,	LGD	26	0	none	EA + TEF type C, vertebral anomaly, coarctation of aorta	VUS
CHERP	c.1306-1G > A	,,	LGD	23.5	1	none	EA + TEF type C, renal ectopia, atrial septal defect, scoliosis	VUS
IL32	c.450_451insC	p.G151Rfs*13	LGD	.	0	none	EA + TEF long gap, duodenal atresia, small hole in heart	VUS
RASA2	c.82del	p.D28Tfs*32	LGD	.	0	none	EA + TEF type C, extra ribs, congenital scoliosis, developmental delay	VUS
AMACR	c.197dup	p.R67Afs*75	LGD	.	0.03	alpha-methylacyl-CoA racemase deficiency (AR-614307); bile acid synthesis defect (AR-214950)	EA + TEF type C and developmental delay	pathogenic
HACE1	c.805C > T	p.R269*	LGD	40	0	spastic paraparesis and psychomotor retardation with or without seizures (AR-616756)	EA + TEF type D, ventricular septal defect, and atrial septal defect	pathogenic
MANBAL	c.72C > G	p.Y24*	LGD	34	0.03	none	EA + TEF type C, short gap	VUS

(Continued on next page)

Table 4. Continued

Gene	Variant	Protein	Variant type	CADD score	gnomAD pLI	OMIM	Individual phenotype	ACMG variant class
CLDN10	c.242T > C	p.M81T	LGD	25.5	0	HELIX syndrome (AR-617671)	EA + TEF type C, short gap	pathogenic
IVD	c.456T > A	p.Y152*	LGD	36	0	isovaleric acidemia (AR-243500)	EA + TEF long gap, hypospadias, minor duplex kidney, developmental delay	pathogenic
OR5K4	c.765del	p.L25Sfs*22	LGD	.	0	none	EA + TEF type C, short gap, ventricular septal defect, horseshoe kidney	VUS
TMPRSS3	c.1048+1G > A	..	LGD	26.1	0	deafness (AR-601072)	EA, duodenal atresia, malrotation, annular pancreas, atrial septal defect, polycystic kidney, imperforate anterior anus, missing rib	pathogenic
TPRI	c.6247-5A > G	..	LGD	.	1	spinocerebellar ataxia 15 (606658); spinocerebellar ataxia 29, congenital nonprogressive (117360); Gillespie syndrome (206700)	EA + TEF type C, atrial septum defect, aortic irregularity, anomaly of both thumbs, vertebral anomalies, spina bifida occulta	pathogenic
KIF17	c.2092C > T	p.Q698*	LGD	35	0	None	EA, vertebral anomalies, arterial canal	VUS
SCP2	c.723del	p.F241Lfs*19	LGD	.	0	leukoencephalopathy with dystonia and motor neuropathy (AR-613724)	EA + TEF type C, left aortic arch, aberrant right subclavian artery, butterfly vertebra, extra ribs, small patent ductus arteriosus	pathogenic

ACMG is American College of Medical Genetics. VUS is variant of uncertain significance.

respectively). One individual with a *de novo* p.G365S *SMAD6* with a CADD score of 32 has a phenotype partially overlapping with conditions associated with *SMAD6* and may represent an expansion of the phenotypes associated with *SMAD6*. One individual with a *de novo* p.T647I variant in *GLS* with a CADD score of 27.1 has a phenotype that at the age of 2 does not overlap with OMIM: 618339 with infantile cataracts, skin abnormalities, and intellectual disability. Of the 24 cases with *de novo* LGD variants, 21 were associated with complex phenotypes (Table 4).

Protein-altering variants in complex cases are involved in endosome trafficking and developmental pathways

While complex cases have a significant burden of *de novo* variants, no one gene harbors more than one LGD or missense *de novo* variant, making it impossible to identify individual risk genes with sufficient statistical support. To investigate the aggregate properties of risk genes, we performed pathway enrichment analysis on protein-altering *de novo* variants in complex cases (n = 126). We focused on GO pathways and HPO terms. To ensure sufficient statistical power, we only considered the pathways that are expected to have at least two protein-altering variants by chance in 126 subjects. We compared the observed variants in each pathway to the expected number of variants estimated from background mutation rate and tested the enrichment using a Poisson test. We corrected the multi-testing p values to FWER based on simulations. Eight GO pathways and five HPO terms are enriched with protein-altering *de novo* variants with FWER ≤ 0.05 (Figure 1A, Table S7). The enriched GO pathways are related to autophagy processes, membrane regulation, and intracellular transport and localization, while the HPO terms are related to other developmental disorders (Figure 1B). A total of 86 genes are involved in at least one significant pathway. Fifty-five genes are involved in endocytosis and transcytosis pathways. Forty-five genes are involved in pathways related to other developmental disorders. The enrichment in GO pathways is mostly driven by *de novo* missense variants, whereas the enrichment in HPO terms is driven by both LGD and missense variants (Figure 1A). These results remain consistent if we exclude the two cases with the 22q11 deletion (Table S8). These findings are consistent with animal model studies in which pleiotropic signaling pathways and endosome-mediated epithelial remodeling are required for tracheoesophageal morphogenesis.²

We also investigated the functional interactions among the genes (n = 143) with protein-altering *de novo* variants in complex cases. Based on StringDB (v11.0),³⁰ the number of protein-protein interactions is significantly larger than expected (PPI enrichment p value = 0.0021; Figure 2).

CRISPR mutation of candidate risk genes in *Xenopus* disrupts trachea-esophageal morphogenesis

The underlying biology of trachea and esophageal development is conserved between humans and other terrestrial




Figure 1. Pathway enrichment analysis

(A) Volcano plot. Each dot represents a pathway. X axis represents the enrichment rate in log scale, and Y axis is the Poisson test p value in log10 scale. The horizontal dashed line marks family-wise error rate (FWER) of 0.05. Significant pathways (FWER < 0.05) are colored by the percentage of LGD variants, and other pathways are colored gray.

(B) Pathway overlaps. Each circle represents a pathway with FWER < 0.05. Circle size is proportional to the number of observed *de novo* variants in the pathway; circle color represents the FWER; edge width is determined by the Jaccard index between two pathways, and edge color represents the correlation coefficient of the two pathways under the null in simulations.

vertebrates, and animal models have proven effective in assessing candidate risk variants from human affected individuals.² We therefore turned to the rapid functional genomics possible in the amphibian *Xenopus*, which is increasingly being used to model human developmental disorders^{39,40} including tracheoesophageal birth defects.¹²

We tested candidate risk variants by CRISPR-Cas9 mutagenesis of the orthologous genes in *Xenopus tropicalis*,

assaying F0 mutant embryos rather than establishing multi-generational lines⁴¹ since this is faster and more closely mimics the *de novo* mutations in human EA/TEF individuals. F0 mutagenesis results in embryos with a range of mosaic indel mutations. We found that F0 mutagenesis of *sox2*, a known EA/TEF risk gene in humans, resulted in a trachea-esophageal phenotype indistinguishable from F2 *sox2*^{-/-} germline mutants with a failure of the foregut to




Figure 2. StringDB of LGD and missense genes in complex cases

Dots are colored to indicate whether it is involved in one of the significant pathways. Constrained genes ($pLI \geq 0.5$) with LGD mutations are colored black. Edge width represents the StringDB score. Genes not involved in any of the annotation groups were not shown.

separate into distinct esophagus and trachea (Figures 3B and 3C). Moreover, unlike human EA individuals with heterozygous $SOX2^{+/-}$ mutations, heterozygous mouse and *Xenopus* $sox2^{+/-}$ mutants do not exhibit tracheoesophageal defects.^{8,42}

We prioritized and selected 18 candidate risk genes to test based on (1) the likelihood that the variant in affected individual was damaging, (2) expression in the *Xenopus* and mouse fetal foregut, and (3) the predicted function focusing on genes implicated in endosome trafficking or signaling pathways that pattern the fetal foregut (Table 5). gRNAs were designed to generate loss-of-function (null) mutations or in a few cases where early embryonic lethality was predicted, an affected individual-like mutation targeting a conserved sequence near the corresponding variant. We genotyped each CRISPR-injected embryo and assessed the trachea-esophageal phenotype in embryos with >40% damaging indel mutations. At 3 days of development (stage NF44), when the trachea and esophagus have normally separated (Figure 3A), tadpoles were fixed and assessed by confocal immunostaining for (Figure 3).

Thirteen of 18 genes screened exhibited defective trachea-esophageal development in >10% of mutated tadpoles (Table 5, Figure 3). The most common phenotype was an LTEC where the trachea and esophagus failed to separate near the larynx (e.g., *sox2*, *eftud2*, *itsn1*) (Figures 3C–3E), or a disorganized esophageal epithelium, likely leading to EA later in development (e.g., *arhgap21* and *disp1*) (Figures 3F and 3G). This failure to separate the embryonic foregut is a typical manifestation commonly

observed in both mouse and *Xenopus* embryos with mutations in known EA risk genes.² Interestingly, several of the gene mutations also resulted in co-occurring defects in other organ systems like the EA/TEF human cases including microphthalmia, microcephaly, and craniofacial malformations. Notably, five genes are implicated in signaling pathways known to regulate foregut patterning (*amer3*, *apc2*, *celsr2*, *disp1*, *smad6*), while five other genes are implicated in endocytosis and/or intracellular trafficking (*abra*, *arhgap21*, *ap1g2*, *itsn1*, *rapgef3*) (Table 5).

Discussion

In this study, we identified 249 *de novo* coding variants in 185 EA/TEF individuals, including 23 LGD variants and 168 missense variants. Only two cases were associated with pathogenic variants in genes previously established to cause EA/TEF, suggesting that most of our findings are identifying genetic associations with EA/TEF in genes not previously associated with EA/TEF. Protein-altering *de novo* variants are enriched in complex cases. Consistent with previous studies of congenital anomalies, those variants showed greater enrichment in constrained genes. Pathway analysis showed that endocytosis, membrane regulation, and intracellular trafficking-related processes are enriched with protein-altering variants. Considering recent findings in mouse and *Xenopus* that endosome-mediated epithelial remodeling acts downstream of Hedgehog-Gli signaling to regulate tracheoesophageal morphogenesis,¹² it is possible




Figure 3. CRISPR-mutation of candidate risk genes in *Xenopus* disrupts trachea-esophagus morphogenesis

(A–G) Representative confocal microscopy images of NF44 foregut from *Xenopus* CRISPR mutants. *Sox2* F0 CRISPR mutants (C) have the same trachea-esophageal phenotype as *sox2*^{-/-} F2 germline mutants (B), validating the F0 screen. Compared to control *tyr* mutations in which the trachea (t) and esophagus (e) have completely separated (A), mutation of 13/18 genes caused a failure of the foregut to separate into distinct trachea and esophagus (D–E and H–L) and/or resulted in a disrupted esophagus with multiple lumens (F and G). Dashed lines indicate the esophagus, trachea, and foregut lumens. Arrows point to a tracheoesophageal cleft. The number of embryos with a TED phenotype/total injected. Scale bars represent 50 μ m.

that disruption in endocytic vesicular trafficking may be a common mechanism in many EA/TEF individuals.

Endocytic vesicular trafficking is regulated by small GTPases (Rab/Rho) that link endocytosis of membrane-bound vesicles to the actin intracellular transport machinery, which moves vesicles to different subcellular compartments: to lysosomes in the case of autophagy, to different membrane domains in the case of recycling endosomes, from the Golgi and ER to the cell surface for maturation of membrane proteins, and from basal to apical membranes in the case of transcytosis.^{43–45} Endocytic trafficking can influence morphogenesis in many ways: by changing cell shape, by dynamic remodeling of cell adhesion and junctional complexes, and by regulation of cell migration or cell signaling.^{46–50} Moreover, one of the candidate genes that we tested, *ITSN1*, encodes a multidomain adaptor protein that coordinates the intracellular transport of endocytic vesicles.⁵¹ *ITSN1* is also an autism risk loci and consistent with the neurodevelopmental disorders also present in the EA/TEF individual, *Itsn1* is required for neural dendrite forma-

tion in rodents, where it physically interacts with core endocytic protein *Dnm2* acting as a Cdc42-GEF to promote actin-mediated endosome transport.^{52,53} Thus, the finding that several candidate genes validated in *Xenopus* are implicated in endocytosis or GTPase activity (*abra*, *argap21*, *aplg2*, *itsn1*, *rapgef3*, *rab3gap2*) suggests that the EA/TEF in the individuals may have been due to disrupted foregut morphogenesis.

Our analysis also revealed that LGD and missense variants in complex cases are involved in other developmental disorders, suggesting disruptions to pleiotropic pathways with roles in multiple organ systems. Indeed, *Xenopus* mutagenesis validated several genes implicated in signaling pathways known to regulate foregut patterning as well as the development of other organ systems including *amer3*, *apc2*, and *celsr2* in the Wnt pathway, *smad6* and *sox2* in the BMP pathway, and *disp1* required for secretion of Hedgehog ligands. In the future, as more functional data are collected on EA/TEF risk variants, it may be possible to link distinct signaling pathways or

Table 5. EA/TEF candidate genes screened in *Xenopus*.

Gene	Function	<i>Xenopus</i> TED frequency (n)	Co-occurring defects	% indels	Mutation type
<i>sox2</i>	transcription factor	100% (14)		100% (germline)	null
<i>sox2</i>	transcription factor	65% (17)	microphthalmia	91%	null
<i>disp1</i>	Hedgehog signaling	71% (14)		62%	null
<i>amer3</i>	Wnt signaling	62% (21)		57%	null
<i>eftud2</i>	mRNA splicing	55% (22)	microphthalmia	92%	affected individual-like
<i>abra</i>	Rho signaling	45% (20)	craniofacial	92%	null
<i>itsn1</i>	endocytosis	47% (19)	microcephaly	71%	null
<i>itsn1</i>	endocytosis	42% (43)		72%	affected individual-like
<i>apc2</i>	Wnt signaling	37% (19)		87%	null
<i>smad6</i>	BMP signaling	32% (31)	craniofacial heart looping	68%	affected individual-like
<i>arhgap21</i>	Rho signaling	30% (23)	craniofacial	86%	null
<i>itgb4</i>	integrin	29% (14)	heart looping	76%	null
<i>ap1g2</i>	endocytosis	24% (17)	microphthalmia	92%	null
<i>rapgef3</i>	Ras signaling	20% (5)		91%	null
<i>celsr2</i>	Wnt/PCP signaling	17% (24)		79%	null
<i>ptpn14</i>	RTK signaling	13% (23)		94%	null
<i>add1</i>	cytoskeleton	8% (24)	craniofacial	89%	null
<i>map4k3</i>	MAPK signaling	8% (13)		71%	null
<i>rab3gap2</i>	endocytosis	6% (18)		81%	null
<i>arhgap17</i>	Rho signaling	0% (11)	gut looping	88%	null
<i>pcdh1</i>	cell-cell adhesion	0% (7)		47%	null
<i>tyr</i> (control)	pigmentation	2% (71)		n/d	null

TED, tracheoesophageal defect.

cellular mechanisms such as endocytosis to different co-occurring anomalies in specific organ systems.

Overall, the genetics of EA/TEF is heterogeneous. With 126 complex cases that are overall significantly enriched with *de novo* protein-altering variants, we did not find a gene with such variants in multiple cases. This indicates that the number of risk genes contributing through *de novo* variants is large. A sustained effort to expand the cohort with genome sequencing is critical to improve statistical power to identify risk genes in humans.

EA/TEF, like most other congenital anomalies, does not yet have a ClinGen expert panel and has not yet had a formal ClinGen evidence review to establish gene-disease validity for the phenotype of EA/TEF. Some syndromes have been assessed by the syndromic disorders expert panel, but none of the assessed conditions is frequently or consistently associated with EA/TEF. Given the apparent genetic heterogeneity and the small number of genomic studies of EA/TEF, it will likely be some time before there is sufficient evidence to assess any genes beyond perhaps those associated with Fanconi anemia as having more than limited evidence. However, functional data such as that we present in this manuscript add significantly to the evidence review once there are six or

more independent *de novo* predicted loss-of-function individuals with a similar phenotype.

One interesting observation is that all CRISPR-generated *Xenopus* mutants had severe tracheoesophageal clefts rather than atresia or fistulas. We expect that this is because the CRISPR editing strategy results in high mutagenesis rates and often loss-of-function alleles resulting in more severe tracheoesophageal phenotypes, in contrast to the individuals who have heterozygous variants. Indeed, in all most all reported cases where EA/TEF risk alleles have been modeled in mouse or *Xenopus*, heterozygous variants do not result in an EA/TEF phenotype, whereas null mutations exhibit a cleft with a single undivided foregut.² This difference could be due to hypomorphic human variants versus null alleles in animals. In humans, null alleles in pleiotropic developmental genes are likely to be embryonic lethal and may not be viable to term. An additional factor is likely to be the fact that animal models are inbred, whereas the humans have diverse genetic backgrounds, likely associated with modifying alleles. In the future it will be important to test these possibilities with the exact affected individual alleles in animal models to obtain a better assess the genotype-phenotype relationship of these conditions.

Limitations of this study

Our study had limited statistical power to identify individual risk genes of EA/TEF based solely upon the human genetic studies due to the limited sample size. Collaborative human genetic studies of EA/TEF will be necessary to increase those sample sizes and better understand the spectrum of phenotypes associated with each gene. If somatic mutations play a significant role in disease pathogenesis, genetic analyses of blood or saliva may be insufficient to detect these genetic variants.

However, even with a modest human sample size with only a single human with a *de novo* variant in the gene, we demonstrate the ability to effectively select disease-causing variants and functionally confirm the majority of the candidate genes using a moderate throughput F0 mutagenesis system. The combination of human genetics and model organism modeling is powerful for rare human genetic conditions associated with morphological defects. By examining pathways common across genes, we implicate endocytosis, membrane regulation, and intracellular trafficking in tracheoesophageal development, and these same processes are likely related to other congenital anomalies and neurodevelopmental disorders.

Data and code availability

The code generated during this study is available at GitHub: <https://github.com/ShenLab/pathways> pathways, which contains the code for pathway enrichment analysis of *de novo* variants with family-wise error rate estimation.

The accession number for the raw whole genome sequencing data reported in this paper is dbGaP:phs002161.

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.xhgg.2022.100107>.

Acknowledgments

We would like to thank the individuals with EA/TEF and their families who participated in the study and the TOFS UK organization for their support of the study. We thank Patricia Lanzano, Jian-gyuan Hu, Liyong Deng, and Charles LeDuc from Columbia University for technical assistance. We would like to thank the study coordinators Gentry Wools (UT-Southwest), Amanda Schreibis (Cincinnati Children's Hospital) and Andrew Mason (Oregon Health and Science University) for their assistance. We also thank Dr. Na Zhu, Dr. Xueya Zhou, and other members of Chung and Shen labs for helpful discussions. The whole genome sequencing data were generated through NIH Gabriella Miller Kids First Pediatric Research Program (X01HL145692 and X01HD100705). Microscopy was performed at the CCHMC Confocal Imaging Core. The work was support by NIH grants P01HD093363 (A.M.Z., Y.S., and W.K.C.), R01GM120609 (G.Z., Y.S.), and R03HL147197 (Y.S.). N.A.E. is supported by a Canadian Institutes of Health Research postdoctoral fellowship. We acknowledge Marko Horb and Danielle Jordan at the National *Xenopus* Resource for generating *sox2* germline mutant *Xenopus* tadpoles for this study (RRID: SCR_013731).

Author contributions

W.K.C., Y.S. and A.M.Z. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: W.K.C., Y.S. and A.M.Z. Acquisition, analysis, or interpretation of data: G.Z., P.A., N.A.E., J.J.H., C.F., P.K., W.M., J.K., M.E.F., D.S., E.F., A.K., S.F., A.P.K., A.M.Z., Y.S. and W.K.C. Drafting of the manuscript: G.Z., P.A., N.A.E., A.M.Z., Y.S. and W.K.C. Critical revision of the manuscript for important intellectual content: G.Z., P.A., N.A.E., J.J.H., C.F., P.K., W.M., J.K., M.E.F., D.S., E.F., A.K., S.F., A.P.K., A.M.Z., Y.S. and W.K.C. Statistical analysis: G.Z., P.A., N.A.E., A.M.Z., and Y.S. *Xenopus* experimental design: N.A.E., A.K. *Xenopus* experiment: N.A.E., A.K., S.F., A.P.K. Supervision: A.M.Z., Y.S. and W.K.C. The authors read and approved the final manuscript.

Declaration of interests

The authors declare no competing interests.

Received: August 24, 2021

Accepted: April 6, 2022

Corrected online: June 17, 2022

References

1. Nassar, N., Csaky-Szunyogh, M., Feldkamp, M.L., Khoshnood, B., Landau, D., Lelong, N., Lopez-Camelo, J.S., Lowry, R.B., McDonnell, R., Merlob, P., et al. (2012). Prevalence of esophageal atresia among 18 international birth defects surveillance programs. Birth Defects Res. A. 94, 893–899. <https://doi.org/10.1002/bdra.23067>.
2. Edwards, N.A., Shacham-Silverberg, V., Weitz, L., Kingma, P.S., Shen, Y., Wells, J.M., Chung, W.K., and Zorn, A.M. (2021). Developmental basis of trachea-esophageal birth defects. Dev. Biol. 477, 85–97. <https://doi.org/10.1016/j.ydbio.2021.05.015>.
3. van Lennep, M., Singendonk, M.M.J., Dall'Oglio, L., Gottrand, F., Krishnan, U., Terheggen-Lagro, S.W.J., Omari, T.I., Benninga, M.A., and van Wijk, M.P. (2019). Oesophageal atresia. Nat. Rev. Dis. Primers 5, 26. <https://doi.org/10.1038/s41572-019-0077-0>.
4. Stoll, C., Alembik, Y., Dott, B., and Roth, M.P. (2017). Associated anomalies in cases with esophageal atresia. Am. J. Med. Genet. A. 173, 2139–2157. <https://doi.org/10.1002/ajmg.a.38303>.
5. Shaw-Smith, C. (2010). Genetic factors in esophageal atresia, tracheo-esophageal fistula and the VACTERL association: roles for FOXF1 and the 16q24.1 FOX transcription factor gene cluster, and review of the literature. Eur. J. Med. Genet. 53, 6–13. <https://doi.org/10.1016/j.ejmg.2009.10.001>.
6. Li, Y., Litigting, Y., Ten Dijke, P., and Chiang, C. (2007). Aberrant Bmp signaling and notochord delamination in the pathogenesis of esophageal atresia. Dev. Dyn. 236, 746–754. <https://doi.org/10.1002/dvdy.21075>.
7. Que, J., Choi, M., Ziel, J.W., Klingensmith, J., and Hogan, B.L. (2006). Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation 74, 422–437. <https://doi.org/10.1111/j.1432-0436.2006.00096.x>.
8. Que, J., Okubo, T., Goldenring, J.R., Nam, K.T., Kurotani, R., Morrissey, E.E., Taranova, O., Pevny, L.H., and Hogan, B.L.M. (2007). Multiple dose-dependent roles for Sox2 in the

- patterning and differentiation of anterior foregut endoderm. *Development* 134, 2521–2531. <https://doi.org/10.1242/dev.003855>.
9. Rankin, S.A., Han, L., McCracken, K.W., Kenny, A.P., Anglin, C.T., Grigg, E.A., Crawford, C.M., Wells, J.M., Shannon, J.M., and Zorn, A.M. (2016). A retinoic acid-hedgehog cascade coordinates mesoderm-inducing signals and endoderm competence during lung specification. *Cell Rep.* 16, 66–78. <https://doi.org/10.1016/j.celrep.2016.05.060>.
 10. Gordon, C.T., Boute-Benejean, O., Caumes, R., Delobel, B., Dietrich, K., Gaillard, D., Gonzales, M., Lacombe, D., Escande, F., Manouvrier-Hanu, S., et al. (2012). EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia. *J. Med. Genet.* 49, 737–746. <https://doi.org/10.1136/jmedgenet-2012-101173>.
 11. Wang, J., Ahimaz, P.R., Hashemifar, S., Khlevner, J., Picoraro, J.A., Middlesworth, W., Elfify, M.M., Que, J., Shen, Y., and Chung, W.K. (2021). Novel candidate genes in esophageal atresia/tracheoesophageal fistula identified by exome sequencing. *Eur. J. Hum. Genet.* 29, 122–130. <https://doi.org/10.1038/s41431-020-0680-2>.
 12. Nasr, T., Trisno, S.L., Cha, S.W., Wells, J.M., Kofron, M.J., Zorn, A.M., Mancini, P., Rankin, S.A., Edwards, N.A., Agricola, Z.N., et al. (2019). Endosome-mediated epithelial remodeling downstream of hedgehog-gli is required for tracheoesophageal separation. *Dev. Cell* 51, 665–674.e6. <https://doi.org/10.1016/j.devcel.2019.11.003>.
 13. Qi, H., Lim, F.Y., Crombleholme, T., Cusick, R., Azarow, K., Danko, M.E., Chung, D., Warner, B.W., Mychaliska, G.B., Potoka, D., et al. (2018). De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders. *PLoS Genet.* 14, e1007822. <https://doi.org/10.1371/journal.pgen.1007822>.
 14. Richter, F., Parfenov, M., Homsy, J., Gorham, J.M., Manheimer, K.B., Velinder, M., Farrell, A., Marth, G., Schadt, E.E., Kaltman, J.R., et al. (2020). Genomic analyses implicate noncoding de novo variants in congenital heart disease. *Nat. Genet.* 52, 769–777. <https://doi.org/10.1038/s41588-020-0652-z>.
 15. Poplin, R., Gross, S.S., Dorfman, L., McLean, C.Y., DePristo, M.A., Chang, P.C., Alexander, D., Schwartz, S., Colthurst, T., Ku, A., et al. (2018). A universal SNP and small-indel variant caller using deep neural networks. *Nat. Biotechnol.* 36, 983–987. <https://doi.org/10.1038/nbt.4235>.
 16. Karczewski, K.J., Francioli, L.C., MacArthur, D.G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443. <https://doi.org/10.1038/ey.17.14.3>.
 17. Lek, M., Tukiainen, T., Birnbaum, D.P., Kosmicki, J.A., Duncan, L.E., Estrada, K., Zhao, F., Zou, J., Pierce-Hoffman, E., Berghout, J., et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291. <https://doi.org/10.1038/nature19057>.
 18. Jagannathan, K., Chow, E.D., Kanterakis, E., Gao, H., Kia, A., Batzoglou, S., Sanders, S.J., Farh, K.K.H., Kyriazopoulou Panagiotopoulou, S., McRae, J.F., et al. (2019). Predicting splicing from primary sequence with deep learning. *Cell* 176, 535–548.e24. <https://doi.org/10.1016/j.cell.2018.12.015>.
 19. Qiao, L., Nees, S., Khlevner, J., Lim, F.Y., Crombleholme, T., Cusick, R., Azarow, K., Danko, M.E., Chung, D., Warner, B.W., et al. (2020). Likely damaging de novo variants in congenital diaphragmatic hernia patients are associated with worse clinical outcomes. *Genet. Med.* 22, 2020–2028. <https://doi.org/10.1038/s41436-020-0908-0>.
 20. Abzyov, A., Urban, A.E., Snyder, M., and Gerstein, M. (2011). CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. *Genome Res.* 21, 974–984. <https://doi.org/10.1101/gr.114876.110>.
 21. Layer, R.M., Chiang, C., Quinlan, A.R., and Hall, I.M. (2014). LUMPY: a probabilistic framework for structural variant discovery. *Genome Biol.* 15, R84. <https://doi.org/10.1186/gb-2014-15-6-r84>.
 22. Chiang, C., Layer, R.M., Faust, G.G., Lindberg, M.R., Rose, D.B., Garrison, E.P., Marth, G.T., Quinlan, A.R., and Hall, I.M. (2015). SpeedSeq: ultra-fast personal genome analysis and interpretation. *Nat. Methods* 12, 966–968. <https://doi.org/10.1038/nmeth.3505>.
 23. Teschendorff, A.E., Zhu, T., Breeze, C.E., and Beck, S. (2020). EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data. *Genome Biol.* 21, 221. <https://doi.org/10.1186/s13059-020-02126-9>.
 24. Rehm, H.L., Plon, S.E., Ramos, E.M., Sherry, S.T., Watson, M.S., Berg, J.S., Brooks, L.D., Bustamante, C.D., Evans, J.P., Landrum, M.J., et al. (2015). ClinGen—the clinical genome Resource. *N. Engl. J. Med.* 372, 2235–2242. <https://doi.org/10.1056/nejmrs1406261>.
 25. Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M., Rajan, D., Van Vooren, S., Moreau, Y., Pettett, R.M., and Carter, N.P. (2009). DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. *Am. J. Hum. Genet.* 84, 524–533. <https://doi.org/10.1016/j.ajhg.2009.03.010>.
 26. Samocha, K.E., Wall, D.P., MacArthur, D.G., Gabriel, S.B., DePristo, M., Purcell, S.M., Palotie, A., Boerwinkle, E., Buxbaum, J.D., Cook, E.H., et al. (2014). A framework for the interpretation of de novo mutation in human disease. *Nat. Genet.* 46, 944–950. <https://doi.org/10.1038/ng.3050>.
 27. Ware, J.S., Samocha, K.E., Homzy, J., and Daly, M.J. (2015). Interpreting de novo Variation in Human Disease Using denovoLyzer. *Curr. Protoc. Hum. Genet.* 87, 7.25.1–7.25.15. <https://doi.org/10.1002/0471142905.hg0725s87>.
 28. Mootha, V.K., Houstis, N., Daly, M.J., Patterson, N., Mesirov, J.P., Golub, T.R., Tamayo, P., Spiegelman, B., Lander, E.S., Hirschhorn, J.N., et al. (2003). PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34, 267–273. <https://doi.org/10.1038/ng1180>.
 29. Subramanian, A., Mesirov, J.P., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U S A* 102, 15545–15550. <https://doi.org/10.1073/pnas.0506580102>.
 30. Szklarczyk, D., Jensen, L.J., Mering, C., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N.T., et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 47, D607–D613. <https://doi.org/10.1093/nar/gky1131>.

31. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* *13*, 2498–2504. <https://doi.org/10.1101/gr.123930>.
32. Lane, M., and Khokha, M.K. (2021). Obtaining *Xenopus tropicalis* embryos by in vitro fertilization. *Cold Spring Harb. Protoc.* *2022*. pdb.prot106351. <https://doi.org/10.1101/pdb.prot106351>.
33. Lane, M., and Khokha, M.K. (2021). Obtaining *Xenopus tropicalis* embryos by natural mating. *Cold Spring Harb. Protoc.* *2022*. pdb.prot106609. <https://doi.org/10.1101/pdb.prot106609>.
34. Moreno-Mateos, M.A., Vejnar, C.E., Beaudoin, J.D., Fernandez, J.P., Mis, E.K., Khokha, M.K., and Giraldez, A.J. (2015). CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. *Nat. Methods* *12*, 982–988. <https://doi.org/10.1038/nmeth.3543>.
35. Fortriede, J.D., Lotay, V.S., Ponferrada, V.G., Karimi, K., Zorn, A.M., Vize, P.D., Pells, T.J., Chu, S., Chaturvedi, P., Wang, D., et al. (2020). Xenbase: deep integration of GEO & SRA RNA-seq and ChIP-seq data in a model organism database. *Nucleic Acids Res.* *48*, D776–D782. <https://doi.org/10.1093/nar/gkz933>.
36. Hsiau, T., Conant, D., Rossi, N., Maures, T., Waite, K., Yang, J., Joshi, S., Kelso, R., Holden, K., Enzmann, B.L., et al. (2019). Inference of CRISPR edits from sanger trace data. Preprint at bioRxiv. <https://doi.org/10.1101/251082>.
37. Satterstrom, F.K., Stevens, C., Reichert, J., Mulhern, M.S., Artyomov, M., Gerges, S., Sheppard, B., Xu, X., Bhaduri, A., Norman, U., et al. (2020). Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell* *180*, 568–584. <https://doi.org/10.1016/j.cell.2019.12.036>.
38. Richards, S., Voelkerding, K., Rehm, H.L., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. *Genet. Med.* *17*, 405–424. <https://doi.org/10.1038/gim.2015.30>.
39. Fakhro, K.A., Choi, M., Ware, S.M., Belmont, J.W., Towbin, J.A., Lifton, R.P., Khokha, M.K., and Brueckner, M. (2011). Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. *Proc. Natl. Acad. Sci. U S A* *108*, 2915–2920. <https://doi.org/10.1073/pnas.1019645108>.
40. Willsey, H.R., Kim, A., Anderson, A.S., Shin, D., Seyler, M., Nowakowski, T.J., Harland, R.M., Willsey, A.J., State, M.W., Exner, C.R.T., et al. (2021). Parallel in vivo analysis of large-effect autism genes implicates cortical neurogenesis and estrogen in risk and resilience. *Neuron* *109*, 788–804.e8. <https://doi.org/10.1016/j.neuron.2021.01.002>.
41. Bhattacharya, D., Marfo, C.A., Li, D., Lane, M., and Khokha, M.K. (2015). CRISPR/Cas9: an inexpensive, efficient loss of function tool to screen human disease genes in *Xenopus*. *Dev. Biol.* *408*, 196–204. <https://doi.org/10.1016/j.ydbio.2015.11.003>.
42. Trisno, S.L., Mandegar, M.A., Wells, S.I., Zorn, A.M., Wells, J.M., Philo, K.E.D., McCracken, K.W., Cata, E.M., Ruiz-Torres, S., Rankin, S.A., et al. (2018). Esophageal organoids from human pluripotent stem cells delineate Sox2 functions during esophageal specification. *Cell Stem Cell* *23*, 501–515.e7. <https://doi.org/10.1016/j.stem.2018.08.008>.
43. Grant, B.D., and Donaldson, J.G. (2009). Pathways and mechanisms of endocytic recycling. *Nat. Rev. Mol. Cell Biol.* *10*, 597–608. <https://doi.org/10.1038/nrm2755>.
44. Naslavsky, N., and Caplan, S. (2018). The enigmatic endosome - sorting the ins and outs of endocytic trafficking. *J. Cell Sci.* *131*, jcs216499. <https://doi.org/10.1242/jcs.216499>.
45. Serra, N.D., and Sundaram, M.V. (2021). Transcytosis in the development and morphogenesis of epithelial tissues. *EMBO J.* *40*, e106163. <https://doi.org/10.15252/embj.2020106163>.
46. Lee, J.Y., and Harland, R.M. (2010). Endocytosis is required for efficient apical constriction during *Xenopus* gastrulation. *Curr. Biol.* *20*, 253–258. <https://doi.org/10.1016/j.cub.2009.12.021>.
47. Bruser, L., and Bogdan, S. (2017). Adherens junctions on the move-membrane trafficking of E-cadherin. *Cold Spring Harb. Perspect. Biol.* *9*, a029140. <https://doi.org/10.1101/cshperspect.a029140>.
48. Mathew, R., Rios-Barrera, L.D., Machado, P., Schwab, Y., and Leptin, M. (2020). Transcytosis via the late endocytic pathway as a cell morphogenetic mechanism. *EMBO J.* *39*, e105332. <https://doi.org/10.15252/embj.2020105332>.
49. Kowalczyk, I., Lee, C., Schuster, E., Hoeren, J., Trivigno, V., Riedel, L., Gorre, J., Wallingford, J.B., Hammes, A., and Feistel, K. (2021). Neural tube closure requires the endocytic receptor Irp2 and its functional interaction with intracellular scaffolds. *Development* *148*, dev195008.
50. Yoon, J., Garo, J., Lee, M., Sun, J., Hwang, Y.S., and Daar, I.O. (2021). Rab11fip5 regulates telencephalon development via ephrinb1 recycling. *Development* *148*, dev196527.
51. Hussain, N.K., Yamabhai, M., Ramjaun, A.R., Guy, A.M., Baranes, D., O'Bryan, J.P., Der, C.J., Kay, B.K., and McPherson, P.S. (1999). Splice variants of intersectin are components of the endocytic machinery in neurons and nonneuronal cells. *J. Biol. Chem.* *274*, 15671–15677. <https://doi.org/10.1074/jbc.274.22.15671>.
52. Yu, Y., Chu, P.Y., Bowser, D.N., Keating, D.J., Dubach, D., Harper, I., Tkalcevic, J., Finkelstein, D.I., and Pritchard, M.A. (2008). Mice deficient for the chromosome 21 ortholog Itsn1 exhibit vesicle-trafficking abnormalities. *Hum. Mol. Genet.* *17*, 3281–3290. <https://doi.org/10.1093/hmg/ddn224>.
53. Gryaznova, T., Gubar, O., Burdyniuk, M., Kropyvko, S., and Rynditch, A. (2018). WIP/ITSN1 complex is involved in cellular vesicle trafficking and formation of filopodia-like protrusions. *Gene* *674*, 49–56. <https://doi.org/10.1016/j.gene.2018.06.078>.